Traduction de «department of clinical » (Néerlandais → Français) :

Department of Clinical Chemistry, Université de Gent Microbiology and Immunology De Pintelaan 185 9000 Ghent Belgium Toegekend bedrag: € 216 000, verdeeld over 4 jaar
Department of Clinical Chemistry, Université de Gent Microbiology and Immunology De Pintelaan 185 9000 Ghent Belgium Montant octroyé: € 216 000, répartis sur 4 ans

Acknowledgements: Voor haar waardevolle bijdrage in het gedeelte over meta-analyse: Cécile Dubois (KCE) Voor hun bijdrage bij het scoren van de indicatoren: Raf Brouns en Matthieu Rutgers (Belgian Stroke Council) Voor het valideren van de informatie over hun land: Zweden: Kiell Asplund (Chair, Risks Stroke Umeal), Bo Norrving (Professor, Lund University-Steering committee member Riks stroke) Nederland: Martien Limburg (Neuroloog, Flevoziekenhuis, Almere, Stichting Kennisnetwerk); Schotland: Martin Dennis (Division of Clinical Neurosciences – Western General Hospital University of Edinburgh), Peter Langhorne (Professor of Stroke Care, Cardiovascular and Medical Sciences Division – University of Glasgow) Verenigd Koninkrijk: Patrick Gompertz (Barts and the London Brain Attack Center, London), Gill Gluckie (Clinical lead, stroke, Guy’s and St. Thomas’ hospital, clinical lead, S/East London stroke network) Frankrijk: France Woimant (Service de neurologie, hôpital Lariboisière, Paris – “Agence Régionale de Santé – Ile-de-France”), Didier Leys (Département de neurologie, Hôpital universitaire de Lille) Duitsland: Peter Heuschmann (Neurologische klinik und poliklinik, Universitätsklinikum Würzburg) German Stroke Register Study Group), E. Bernd Ringelstein (Neurologische klinik und poliklinik, Universitätsklinikum Münster)
Remerciements : Pour son aide précieuse relative à la méta-analyse : Cécile Dubois (KCE) Pour leur contribution au scoring des indicateurs : Raf Brouns et Matthieu Rutgers (Belgian Stroke Council) Pour la validation de la description de leur pays : Suède : Kiell Asplund (Chair, Risks Stroke Umea), Bo Norrving (Professor, Lund University-Steering committee member Riks stroke) Pays-Bas : Martien Limburg (Neuroloog, Flevoziekenhuis, Almere, Stichting Kennisnetwerk) Ecosse : Martin Dennis (Division of Clinical Neurosciences – Western General Hospital University of Edinburgh), Peter Langhorne (Professor of Stroke Care, Cardiovascular and Medical Sciences Division – University of Glasgow) Grande-Bretagne : Patrick Gompertz (Barts and the London Brain Attack Center, London), Gill Gluckie (Clinical lead, stroke, Guy’s and St. Thomas’ hospital, clinical lead, S/East London stroke network) France : France Woimant (Service de neurologie, hôpital Lariboisière, Paris – “Agence Régionale de Santé – Ilede-France”), Didier Leys (Département de neurologie, Hôpital universitaire de Lille) Allemagne : Peter Heuschmann (Neurologische klinik und poliklinik, Universitätsklinikum Würzburg) German Stroke Register Study Group), E. Bernd Ringelstein (Neurologische klinik und poliklinik, Universitätsklinikum Münster)

It is the R&D department’s role to protect the participants in clinical trials by giving scientific advice and evaluating, approving, monitoring and checking applications for clinical research, on the basis of sound scientific knowledge.
It is the R&D department’s role to protect the participants in clinical trials by giving scientific advice and evaluating, approving, monitoring and checking applications for clinical research, on the basis of sound scientific knowledge.

Het Departement Productie & Distributie is belast met de organisatie van Good Clinical Practice/GCP-inspecties en farmacovigilantieinspecties. In 2008 is een risicoanalyse uitgevoerd om een planning voor deze inspecties op te maken.
Le Département Production & Distribution est chargé de mettre en place les inspections Good Clinical Practices (GCP) et pharmacovigilance ; il a réalisé en 2008 une analyse de risque en vue de l’établissement d’un planning relatif à ces inspections.

The R&D (research and development) department is required to deal with all relevant applications for clinical trials.
The R&D (research and development) department is required to deal with all relevant applications for clinical trials.

The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.
The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.

Voor de trillingswaarden van de verschillende voertuigtypes kunt u terecht op de website van het Zweedse Department of Public Health and Clinical Medicine Occupational and Enviromental Medicine.
Pour connaître les valeurs de vibration de différents types de véhicules, l’on peut consulter le site suédoise du Department of Public Health and Clinical Medicine Occupational and Enviromental Medicine.

The R&D (research and development) department is constructed around the following three roles: ●● Clinical trials ●● GCP ●● Scientific advice
The R&D (research and development) department is constructed around the following three roles: ●● Clinical trials ●● GCP ●● Scientific advice

The European Directive 2001/20, transposed in the law of 7 May 2004, forms the basis for the department’s core tasks: ●● Validating, evaluating and assigning approvals for the conduct of clinical trials (including declarations) ●● Strategic preparation of the associated GCP
The European Directive 2001/20, transposed in the law of 7 May 2004, forms the basis for the department’s core tasks: ●● Validating, evaluating and assigning approvals for the conduct of clinical trials (including declarations) ●● Strategic preparation of the associated GCP